Late-stage functionalizations of enantioenriched piperazinederivatives were demonstrated, including synthesis of a drug compoundwith glycogen synthase kinase (GSK)-3β inhibitor activity withpotential for treating Alzheimer’s disease. Here, GSK3B is linked to early-onset autosomal dominant Alzheimer disease.